RecruitingBRAF V600E Mutation
A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma
Eligible age
18+ yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The investigators will evaluate the sensitivity of ctDNA from plasma and CSF at baseline (defined as C1D1) and over time in response to treatment with plixorafenib alone or in combination with retifanlimab in patients with BRAF-V600E mutant glioma refractory to prior therapies.
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
You may not qualify if…
- ✕ Exclusion Arm A Only:
- ✕ Prior RAF dimer disruptor or pan-RAF inhibitor.
- ✕ Exclusion Arm B Only:
- ✕ Prior immunotherapy (of note prior RAF dimer-disruptor or pan-RAF inhibitor is allowed).
- ✕ Known history of clinically significant autoimmune disease that, in the opinion of the investigator, may be exacerbated by immune checkpoint blockade (e.g., multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease), with the following exceptions: Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis or alopecia) not requiring systemic treatment (subjects with a history of flares requiring systemic treatment are excluded), or other autoimmune conditions not expected to recur in the absence of an external trigger are permitted to enroll.
- ✕ Daily systemic steroids \> 4mg daily dexamethasone or equivalent.
- ✕ Have received a live vaccine within 28 days before the planned start of study treatment.
- ✕ Exclusion Both Arms:
Where it's recruiting
Source: ClinicalTrials.gov · NCT06610682 · last updated 2026-09-22